Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 04, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The filing details specific share movements on August 31, 2006, executed by the GlaxoSmithKline Employee Trust ("the GSK Trust"):
- Transfer of 49,186 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Sale of 2,789 Ordinary Shares to participants in the GlaxoSmithKline Share Value Plan at a price of GBP14.94 per share.
- Transfer of 8,134 Ordinary Shares to participants in the GlaxoSmithKline Share Value Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) are interested in shares held in the GSK Trust in the same capacity as other employees. The transactions were notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of shares transferred or sold by the GSK Trust on August 31, 2006.
- Confirm the transaction price of GBP14.94 per share for the GlaxoSmithKline Share Value Plan sales.
- Review the specific plans involved: SmithKline Beecham Employee Share Option Plan 1991 and GlaxoSmithKline Share Value Plan.
- Note that the Company was advised of these transactions on September 1, 2006.